晚期肝癌患者对索拉非尼耐药机制的研究进展

摘要

肝细胞癌是临床中最常见、最具侵袭性的恶性肿瘤之一.索拉非尼是多靶点、多激酶抑制剂,也是公认的治疗晚期原发性肝癌的一线标准治疗药物.但患者对其的耐药性,严重影响了索拉非尼的治疗效果.本文主要从肿瘤微环境、缺氧、上皮细胞间质化、肿瘤干细胞等几个方面对索拉非尼耐药机制的研究进展进行综述.%Hepatocellular carcinoma (HCC) is one of the most common and aggressive malignant tumors in the world. As an orally-available kinase inhibitor, sorafenib is the exclusively standard clinical treatment against advanced hepatocellular carcinoma. However, the increasing level of resistance to sorafenib has seriously affected the therapeutic effect. Herein, we review the potential mechanism of sorafenib resistance in hepatocellular carcinoma from the aspects of microenvironment, hypoxia, epithelial mesenchymal, cancer stem cells and so on.